A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes
Journal
The Journal of clinical endocrinology and metabolism
Journal Volume
107
Journal Issue
10
Pages
E4063
Date Issued
2022-09-28
Author(s)
Chu, Chih-Hsun
Huang, Chien-Ning
Chen, Harn-Shen
Lee, I-Te
Chen, Jung-Fu
Chen, Ching-Chu
Chen, Chung-Sen
Hsieh, Chang-Hsun
Tien, Kai-Jen
Chien, Hung-Yu
Huang, Yu-Yao
Hsu, Jui-Pao
Shane, Guang-Tzuu
Chang, Ai-Ching
Wu, Yen-Chieh
Sheu, Wayne Huey-Herng
Abstract
There is a medical need for effective insulin-independent antidiabetic drugs that can promote pancreatic β-cell function and have a low risk of hypoglycemia in type 2 diabetes mellitus (T2DM) patients. R-form verapamil (R-Vera), which is able to enhance the survival of β-cells and has higher cardiovascular safety margin compared with racemic verapamil, was developed as a novel approach for T2DM treatment.
Subjects
HbA1c; R-form verapamil; antidiabetic drug; metformin; type 2 diabetes
SDGs
Publisher
ENDOCRINE SOC
Type
journal article